Through computational drug screening, we identified Salvianolic acid B (Sal B) as a potent ZFPL1 inhibitor, and subsequent experimental validation confirmed its ability to disrupt ZFPL1‐ASS1 interaction and suppress CRC malignancy. Here, ZFPL1 is linked to colorectal carcinoma.